Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.

Antimicrobial agents and chemotherapy - 1 Aug 2007

Louie Arnold, Deziel Mark R, Liu Weiguo, Drusano George L

Abstract excerpt

Yersinia pestis, the bacterium that causes plague, is a potential agent of biowarfare and bioterrorism. The aminoglycoside antibiotic streptomycin is the gold standard for treatment. However, this recommendation is based on scant animal and clinical data. We used an in vitro pharmacodynamic infec...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colony Count, Microbial
Share to Immunocompetence
Share to Levofloxacin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neutropenia

Share to Ofloxacin

Share to Plague

Share to Streptomycin

Share to Yersinia pestis

Source

Open in PubMed Open full text

Identifiers

PMID: 17517837
DOI: 10.1128/AAC.00073-07
PMCID: PMC1932490

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17517837-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.PMID 17517837Read ↗

Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.Semantic proximity Read ↗

Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.Semantic proximity Read ↗

Analysis of the mutant selection window and killing of Mycoplasma hyopneumoniae for doxycycline, tylosin, danofloxacin, tiamulin, and valnemulin.Semantic proximity Read ↗

Evaluation the kill rate and mutant selection window of danofloxacin against Actinobacillus pleuropneumoniae in a peristaltic pump model.Semantic proximity Read ↗

Phage therapy potentiates second-line antibiotic treatment against pneumonic plagueSemantic proximity Read ↗

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapySemantic proximity Read ↗

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.Semantic proximity Read ↗

Immunosuppression broadens evolutionary pathways to drug resistance and treatment failure during Acinetobacter baumannii pneumonia in miceSemantic proximity Read ↗

Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design.Semantic proximity Read ↗

Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against Itself.Semantic proximity Read ↗

Manipulating virulence factor availability can have complex consequences for infectionsSemantic proximity Read ↗

A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.